ID

14571

Descripción

Azacitidine in Treating Patients With Relapsed Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia Who Have Undergone Stem Cell Transplant; ODM derived from: https://clinicaltrials.gov/show/NCT01083706

Link

https://clinicaltrials.gov/show/NCT01083706

Palabras clave

Versiones (1)
  1. 21/4/16 21/4/16 -
Subido en

21 de abril de 2016

DOI

Para solicitar uno, por favor iniciar sesión.

Licencia

Creative Commons BY 4.0
Comentarios del modelo :

Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.

Volver a los comentarios del modelo
Comentarios de grupo de elementos para :

Comentarios del elemento para :

  • El más nuevo
  • Más antiguo
  • Popular
  • El más nuevo
    • El más nuevo
    • Más antiguo
    • Popular

Sin comentarios

Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.

Eligibility Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities NCT01083706

Inglés

Eligibility Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities NCT01083706

1 formularios  
Inclusion Criteria
Descripción

Inclusion Criteria

Alias
UMLS CUI
C1512693
mds, cmml or aml patients (as diagnosed by world health organization [who] criteria) with evidence of relapse or progression at >= day 28 and < day 100 post-transplant
Descripción

mds

Tipo de datos

boolean

Alias
UMLS CUI [1]
C3463824
recurrent or increased cytogenetic abnormalities by standard karyotype or fluorescence in situ hybridization (fish) (the cytogenetic abnormalities must have been previously documented at some time point between diagnosis and date of stem cell transplant)
Descripción

cytogenetic abnormalities

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0008625
morphologic evidence of recurrence or increased abnormal myeloblasts in peripheral blood or marrow
Descripción

Myeloblast

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0229633
flow cytometric evidence of disease as determined by recurrent or increased abnormal myeloblasts in peripheral blood or marrow
Descripción

Myeloblasts flow cytometric

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0580952
UMLS CUI [1,2]
C0201644
extramedullary relapse (local radiotherapy will be allowed)
Descripción

extramedullary relapse

Tipo de datos

boolean

Alias
UMLS CUI [1]
C2854080
mds, cmml, or aml patients with persistent stable disease or persistent disease with regression at >= day 28 and < day 100 post-transplant; the inclusion of patients with persistent stable or persistent regressing disease in this protocol is not meant to advocate treatment; however, if the attending physician is inclined to offer treatment then these patients would be eligible for this study
Descripción

mds, cmml, or aml patients

Tipo de datos

boolean

Alias
UMLS CUI [1]
C3463824
UMLS CUI [2]
C0023480
persistence of cytogenetic abnormalities by standard karyotype or fish
Descripción

cytogenetic abnormalities

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0008625
persistent morphologic evidence of abnormal myeloblasts (in patients with cmml the monoblastoid population is included) in peripheral blood or marrow
Descripción

abnormal myeloblasts

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0205161
UMLS CUI [1,2]
C0229633
extramedullary persistence or regression
Descripción

Extramedullary

Tipo de datos

boolean

Alias
UMLS CUI [1]
C1517060
Exclusion Criteria
Descripción

Exclusion Criteria

Alias
UMLS CUI
C0680251
refractory disease at time of stem cell transplant; patients who received chemotherapy prior to transplant with no evidence of response by international working group (iwg) criteria
Descripción

Refractory Disease

Tipo de datos

boolean

Alias
UMLS CUI [1]
C1514815
>= 10% bone marrow myeloblasts as measured by morphology
Descripción

Bone marrow myeloblasts

Tipo de datos

boolean

Alias
UMLS CUI [1]
C1993094
evidence of central nervous system (cns) disease at time of relapse by morphology or flow (a diagnostic lumbar puncture [lp] is not required at time of relapse)
Descripción

central nervous system

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0007684
serum creatinine > 2 x uln (upper limit of normal)
Descripción

serum creatinine

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0201976
aspartate aminotransferase (ast)/ alanine aminotransferase (alt) > 2x uln
Descripción

aspartate aminotransferase

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0201899
performance status > 2 (eastern cooperative oncology group [ecog] scale)
Descripción

eastern cooperative oncology group

Tipo de datos

boolean

Alias
UMLS CUI [1]
C1512162
patients with severe disease other than mds, cmml or aml which would be expected to prevent compliance with treatment
Descripción

Protocol Compliance

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0525058
UMLS CUI [2]
C0009488
patients with severe infections (pneumonia, sepsis, etc) within the 2 weeks prior to the anticipated start of protocol treatment
Descripción

severe infections

Tipo de datos

boolean

Alias
UMLS CUI [1]
C3714514
Volver a la parte superior de la página

Similar models

Eligibility Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities NCT01083706

1 formularios
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de datos
Alias
Item Group
C1512693 (UMLS CUI)
mds
Item
mds, cmml or aml patients (as diagnosed by world health organization [who] criteria) with evidence of relapse or progression at >= day 28 and < day 100 post-transplant
boolean
C3463824 (UMLS CUI [1])
cytogenetic abnormalities
Item
recurrent or increased cytogenetic abnormalities by standard karyotype or fluorescence in situ hybridization (fish) (the cytogenetic abnormalities must have been previously documented at some time point between diagnosis and date of stem cell transplant)
boolean
C0008625 (UMLS CUI [1])
Myeloblast
Item
morphologic evidence of recurrence or increased abnormal myeloblasts in peripheral blood or marrow
boolean
C0229633 (UMLS CUI [1])
Myeloblasts flow cytometric
Item
flow cytometric evidence of disease as determined by recurrent or increased abnormal myeloblasts in peripheral blood or marrow
boolean
C0580952 (UMLS CUI [1,1])
C0201644 (UMLS CUI [1,2])
extramedullary relapse
Item
extramedullary relapse (local radiotherapy will be allowed)
boolean
C2854080 (UMLS CUI [1])
mds, cmml, or aml patients
Item
mds, cmml, or aml patients with persistent stable disease or persistent disease with regression at >= day 28 and < day 100 post-transplant; the inclusion of patients with persistent stable or persistent regressing disease in this protocol is not meant to advocate treatment; however, if the attending physician is inclined to offer treatment then these patients would be eligible for this study
boolean
C3463824 (UMLS CUI [1])
C0023480 (UMLS CUI [2])
cytogenetic abnormalities
Item
persistence of cytogenetic abnormalities by standard karyotype or fish
boolean
C0008625 (UMLS CUI [1])
abnormal myeloblasts
Item
persistent morphologic evidence of abnormal myeloblasts (in patients with cmml the monoblastoid population is included) in peripheral blood or marrow
boolean
C0205161 (UMLS CUI [1,1])
C0229633 (UMLS CUI [1,2])
Extramedullary
Item
extramedullary persistence or regression
boolean
C1517060 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
Refractory Disease
Item
refractory disease at time of stem cell transplant; patients who received chemotherapy prior to transplant with no evidence of response by international working group (iwg) criteria
boolean
C1514815 (UMLS CUI [1])
Bone marrow myeloblasts
Item
>= 10% bone marrow myeloblasts as measured by morphology
boolean
C1993094 (UMLS CUI [1])
central nervous system
Item
evidence of central nervous system (cns) disease at time of relapse by morphology or flow (a diagnostic lumbar puncture [lp] is not required at time of relapse)
boolean
C0007684 (UMLS CUI [1])
serum creatinine
Item
serum creatinine > 2 x uln (upper limit of normal)
boolean
C0201976 (UMLS CUI [1])
aspartate aminotransferase
Item
aspartate aminotransferase (ast)/ alanine aminotransferase (alt) > 2x uln
boolean
C0201899 (UMLS CUI [1])
eastern cooperative oncology group
Item
performance status > 2 (eastern cooperative oncology group [ecog] scale)
boolean
C1512162 (UMLS CUI [1])
Protocol Compliance
Item
patients with severe disease other than mds, cmml or aml which would be expected to prevent compliance with treatment
boolean
C0525058 (UMLS CUI [1])
C0009488 (UMLS CUI [2])
severe infections
Item
patients with severe infections (pneumonia, sepsis, etc) within the 2 weeks prior to the anticipated start of protocol treatment
boolean
C3714514 (UMLS CUI [1])
Volver a la parte superior de la página 

Ayuda

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial